NIH R01 · 2025
Blood-based AD biomarkers profile in CAPCOG-TBI study
Sustaining a traumatic brain injury (TBI) can lead to an onset of and/or accelerate Alzheimer’s Disease (AD)-related neurodegeneration process.1Therefore, TBI is considered as a risk factor for AD and AD-related dementias (ADRD).2-5 Understanding of the pathophysiological mechanisms by which TBI contributes to ADRD onset and progression is a prominent research priority for the NIH.2 Recent development of blood-based AD biomarkers such as Aβ42/Aβ40 and phosphorylated tau (p-tau, e.g., p-tau 217) has shown its potential value for preclinical AD diagnosis6 and has been used in longitudinal observational studies and in clinical trials to assess changers in AD pathology.7 Mounting evidence also…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.